Matthew I. Milowsky

机构：University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center · ORCID：0000-0002-8965-8129

发表论文 550 篇 · 总被引 18975 次 · h-index 66

代表论文

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274 (2025 · Annals of Oncology · 被引 39)
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study (2025 · European Urology · 被引 11)
Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study (2025 · Cancer Medicine · 被引 9)
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial (2025 · Nature Medicine · 被引 9)
3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study (2025 · Annals of Oncology · 被引 3)
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers (2025 · CA A Cancer Journal for Clinicians · 被引 2)